305 related articles for article (PubMed ID: 28323492)
1. Regulatory and Exhausted T Cell Responses to AAV Capsid.
Gernoux G; Wilson JM; Mueller C
Hum Gene Ther; 2017 Apr; 28(4):338-349. PubMed ID: 28323492
[TBL] [Abstract][Full Text] [Related]
2. Impact of AAV Capsid-Specific T-Cell Responses on Design and Outcome of Clinical Gene Transfer Trials with Recombinant Adeno-Associated Viral Vectors: An Evolving Controversy.
Ertl HCJ; High KA
Hum Gene Ther; 2017 Apr; 28(4):328-337. PubMed ID: 28042943
[TBL] [Abstract][Full Text] [Related]
3. Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial.
Vandamme C; Adjali O; Mingozzi F
Hum Gene Ther; 2017 Nov; 28(11):1061-1074. PubMed ID: 28835127
[TBL] [Abstract][Full Text] [Related]
4. Muscle-Directed Delivery of an AAV1 Vector Leads to Capsid-Specific T Cell Exhaustion in Nonhuman Primates and Humans.
Gernoux G; Gruntman AM; Blackwood M; Zieger M; Flotte TR; Mueller C
Mol Ther; 2020 Mar; 28(3):747-757. PubMed ID: 31982038
[TBL] [Abstract][Full Text] [Related]
5. Immune responses to AAV in clinical trials.
Mingozzi F; High KA
Curr Gene Ther; 2007 Oct; 7(5):316-24. PubMed ID: 17979678
[TBL] [Abstract][Full Text] [Related]
6. T Cell-Mediated Immune Responses to AAV and AAV Vectors.
Ertl HCJ
Front Immunol; 2021; 12():666666. PubMed ID: 33927727
[TBL] [Abstract][Full Text] [Related]
7. Immune responses to AAV in clinical trials.
Mingozzi F; High KA
Curr Gene Ther; 2011 Aug; 11(4):321-30. PubMed ID: 21557723
[TBL] [Abstract][Full Text] [Related]
8. The Effect of CpG Sequences on Capsid-Specific CD8
Xiang Z; Kurupati RK; Li Y; Kuranda K; Zhou X; Mingozzi F; High KA; Ertl HCJ
Mol Ther; 2020 Mar; 28(3):771-783. PubMed ID: 31839483
[TBL] [Abstract][Full Text] [Related]
9. AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer.
Verdera HC; Kuranda K; Mingozzi F
Mol Ther; 2020 Mar; 28(3):723-746. PubMed ID: 31972133
[TBL] [Abstract][Full Text] [Related]
10. Prevalence Study of Cellular Capsid-Specific Immune Responses to AAV2, 4, 5, 8, 9, and rh10 in Healthy Donors.
Xicluna R; Avenel A; Vandamme C; Devaux M; Jaulin N; Couzinié C; Le Duff J; Charrier A; Guilbaud M; Adjali O; Gernoux G
Hum Gene Ther; 2024 May; 35(9-10):355-364. PubMed ID: 38581431
[TBL] [Abstract][Full Text] [Related]
11. Adeno-Associated Viruses (AAV) and Host Immunity - A Race Between the Hare and the Hedgehog.
Rapti K; Grimm D
Front Immunol; 2021; 12():753467. PubMed ID: 34777364
[TBL] [Abstract][Full Text] [Related]
12. Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors.
Veron P; Leborgne C; Monteilhet V; Boutin S; Martin S; Moullier P; Masurier C
J Immunol; 2012 Jun; 188(12):6418-24. PubMed ID: 22593612
[TBL] [Abstract][Full Text] [Related]
13. The complex and evolving story of T cell activation to AAV vector-encoded transgene products.
Mays LE; Wilson JM
Mol Ther; 2011 Jan; 19(1):16-27. PubMed ID: 21119617
[TBL] [Abstract][Full Text] [Related]
14. Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes.
Li H; Murphy SL; Giles-Davis W; Edmonson S; Xiang Z; Li Y; Lasaro MO; High KA; Ertl HC
Mol Ther; 2007 Apr; 15(4):792-800. PubMed ID: 17245353
[TBL] [Abstract][Full Text] [Related]
15. Preclinical models to assess the immunogenicity of AAV vectors.
Ertl HCJ
Cell Immunol; 2019 Aug; 342():103722. PubMed ID: 29195742
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo.
Li C; Hirsch M; DiPrimio N; Asokan A; Goudy K; Tisch R; Samulski RJ
J Virol; 2009 Jul; 83(13):6817-24. PubMed ID: 19369348
[TBL] [Abstract][Full Text] [Related]
17. AAV as an immunogen.
Vandenberghe LH; Wilson JM
Curr Gene Ther; 2007 Oct; 7(5):325-33. PubMed ID: 17979679
[TBL] [Abstract][Full Text] [Related]
18. Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them.
Hareendran S; Balakrishnan B; Sen D; Kumar S; Srivastava A; Jayandharan GR
Rev Med Virol; 2013 Nov; 23(6):399-413. PubMed ID: 24023004
[TBL] [Abstract][Full Text] [Related]
19. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells.
Martino AT; Basner-Tschakarjan E; Markusic DM; Finn JD; Hinderer C; Zhou S; Ostrov DA; Srivastava A; Ertl HC; Terhorst C; High KA; Mingozzi F; Herzog RW
Blood; 2013 Mar; 121(12):2224-33. PubMed ID: 23325831
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and toxicity of AAV gene therapy.
Ertl HCJ
Front Immunol; 2022; 13():975803. PubMed ID: 36032092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
